Carbamazepine 0 13 0 13 B-treatment
( 14 15 14 15 O
e.g. 15 19 15 19 O
, 19 20 19 20 O
Tegretol 21 29 21 29 B-treatment
) 29 30 29 30 O

Clarithromycin 0 14 31 45 B-treatment
( 15 16 46 47 O
e.g. 16 20 47 51 O
, 20 21 51 52 O
Biaxin 22 28 53 59 B-treatment
) 28 29 59 60 O

Creatinine 0 10 61 71 B-clinical_variable
≤ 11 12 72 73 O
2.0mg 13 18 74 79 B-upper_bound
/ 18 19 79 80 I-upper_bound
dL 19 21 80 82 I-upper_bound

Cyclosporine 0 12 83 95 B-treatment
( 13 14 96 97 O
e.g. 14 18 97 101 O
Neoral 19 25 102 108 B-treatment
or 26 28 109 111 O
Sandimmune 29 39 112 122 B-treatment
) 39 40 122 123 O

Diltiazem 0 9 124 133 B-treatment
( 10 11 134 135 O
e.g. 11 15 135 139 O
, 15 16 139 140 O
Cardizem 17 25 141 149 B-treatment
) 25 26 149 150 O

Erythromycin 0 12 151 163 B-treatment
( 13 14 164 165 O
e.g. 14 18 165 169 O
, 18 19 169 170 O
Akne 20 24 171 175 B-treatment
- 24 25 175 176 I-treatment
Mycin 25 30 176 181 I-treatment
, 30 31 181 182 O
Ery 32 35 183 186 B-treatment
- 35 36 186 187 I-treatment
Tab 36 39 187 190 I-treatment
) 39 40 190 191 O

Evidence 0 8 192 200 O
of 9 11 201 203 O
leukemia 12 20 204 212 B-cancer
after 21 26 213 218 O
induction 27 36 219 228 B-treatment
therapy 37 44 229 236 I-treatment
which 45 50 237 242 O
, 50 51 242 243 O
in 52 54 244 246 O
the 55 58 247 250 O
opinion 59 66 251 258 O
of 67 69 259 261 O
the 70 73 262 265 O
investigator 74 86 266 278 O
, 86 87 278 279 O
would 88 93 280 285 O
be 94 96 286 288 O
appropriate 97 108 289 300 O
for 109 112 301 304 O
reinduction 113 124 305 316 O
with 125 129 317 321 O
sirolimus 130 139 322 331 B-treatment
/ 139 140 331 332 I-treatment
MEC 140 143 332 335 I-treatment
therapy 144 151 336 343 I-treatment

Evidence 0 8 344 352 O
of 9 11 353 355 O
leukemia 12 20 356 364 B-cancer
recurrence 21 31 365 375 O
after 32 37 376 381 O
a 38 39 382 383 O
nadir 40 45 384 389 B-treatment
bone 46 50 390 394 I-treatment
marrow 51 57 395 401 I-treatment
biopsy 58 64 402 408 I-treatment
demonstrates 65 77 409 421 O
no 78 80 422 424 O
evidence 81 89 425 433 O
of 90 92 434 436 O
residual 93 101 437 445 B-cancer
leukemia 102 110 446 454 I-cancer

Intrathecal 0 11 455 466 B-treatment
methotrexate 12 24 467 479 I-treatment
and 25 28 480 483 O
cytarabine 29 39 484 494 B-treatment
are 40 43 495 498 O
permissible 44 55 499 510 O

Itraconazole 0 12 511 523 B-treatment
( 13 14 524 525 O
e.g. 14 18 525 529 O
, 18 19 529 530 O
Sporanox 20 28 531 539 B-treatment
) 28 29 539 540 O

Ketoconazole 0 12 541 553 B-treatment
( 13 14 554 555 O
e.g. 14 18 555 559 O
, 18 19 559 560 O
Nizoral 20 27 561 568 B-treatment
) 27 28 568 569 O

Patients 0 8 570 578 O
must 9 13 579 583 O
be 14 16 584 586 O
able 17 21 587 591 O
to 22 24 592 594 O
sign 25 29 595 599 O
consent 30 37 600 607 O
and 38 41 608 611 O
be 42 44 612 614 O
willing 45 52 615 622 O
and 53 56 623 626 O
able 57 61 627 631 O
to 62 64 632 634 O
comply 65 71 635 641 O
with 72 76 642 646 O
scheduled 77 86 647 656 O
visits 87 93 657 663 O
, 93 94 663 664 O
treatment 95 104 665 674 B-treatment
plan 105 109 675 679 I-treatment
and 110 113 680 683 O
laboratory 114 124 684 694 O
testing 125 132 695 702 O

Patients 0 8 703 711 O
must 9 13 712 716 O
have 14 18 717 721 O
histologic 19 29 722 732 O
evidence 30 38 733 741 O
of 39 41 742 744 O
high 42 46 745 749 O
risk 47 51 750 754 O
acute 52 57 755 760 B-cancer
myeloid 58 65 761 768 I-cancer
leukemia 66 74 769 777 I-cancer

Previously 0 10 778 788 O
untreated 11 20 789 798 O
non 21 24 799 802 B-cancer
- 24 25 802 803 I-cancer
M3 25 27 803 805 I-cancer
AML 28 31 806 809 I-cancer
age 32 35 810 813 B-age
> 36 37 814 815 O
60 37 39 815 817 B-lower_bound
with 40 44 818 822 O
no 45 47 823 825 O
evidence 48 56 826 834 O
of 57 59 835 837 O
favorable 60 69 838 847 O
karyotype 70 79 848 857 O
defined 80 87 858 865 O
by 88 90 866 868 O
presence 91 99 869 877 O
of 100 102 878 880 O
t(8;21)(q22;q22 103 118 881 896 B-cancer
) 118 119 896 897 I-cancer
[ 120 121 898 899 O
AML1 121 125 899 903 O
- 125 126 903 904 O
ETO 126 129 904 907 O
] 129 130 907 908 O
, 130 131 908 909 O
inv16(p13;q22 132 145 910 923 B-cancer
) 145 146 923 924 I-cancer
, 146 147 924 925 O
or 148 150 926 928 O
t(16;16)(p13;q22 151 167 929 945 B-cancer
) 167 168 945 946 I-cancer
[ 169 170 947 948 O
CBFβ;MYH11 170 180 948 958 O
] 180 181 958 959 O
by 182 184 960 962 O
cytogenetics 185 197 963 975 O
, 197 198 975 976 O
FISH 199 203 977 981 O
, 203 204 981 982 O
or 205 207 983 985 O
RT 208 210 986 988 O
- 210 211 988 989 O
PCR 211 214 989 992 O

Previously 0 10 993 1003 O
untreated 11 20 1004 1013 O
secondary 21 30 1014 1023 B-cancer
AML 31 34 1024 1027 I-cancer
( 35 36 1028 1029 O
from 36 40 1029 1033 O
antecedent 41 51 1034 1044 O
hematologic 52 63 1045 1056 B-cancer
malignancy 64 74 1057 1067 I-cancer
or 75 77 1068 1070 O
following 78 87 1071 1080 O
therapy 88 95 1081 1088 B-treatment
with 96 100 1089 1093 O
radiation 101 110 1094 1103 B-treatment
or 111 113 1104 1106 O
chemotherapy 114 126 1107 1119 B-treatment
for 127 130 1120 1123 O
another 131 138 1124 1131 O
disease 139 146 1132 1139 O
) 146 147 1139 1140 O
with 148 152 1141 1145 O
no 153 155 1146 1148 O
evidence 156 164 1149 1157 O
of 165 167 1158 1160 O
favorable 168 177 1161 1170 O
karyotype 178 187 1171 1180 O
defined 188 195 1181 1188 O
by 196 198 1189 1191 O
presence 199 207 1192 1200 O
of 208 210 1201 1203 O
t(8;21)(q22;q22 211 226 1204 1219 O
) 226 227 1219 1220 O
[ 228 229 1221 1222 O
AML1 229 233 1222 1226 O
- 233 234 1226 1227 O
ETO 234 237 1227 1230 O
] 237 238 1230 1231 O
, 238 239 1231 1232 O
inv16(p13;q22 240 253 1233 1246 O
) 253 254 1246 1247 O
, 254 255 1247 1248 O
or 256 258 1249 1251 O
t(16;16)(p13;q22 259 275 1252 1268 O
) 275 276 1268 1269 O
[ 277 278 1270 1271 O
CBFβ;MYH11 278 288 1271 1281 O
] 288 289 1281 1282 O
by 290 292 1283 1285 O
cytogenetics 293 305 1286 1298 O
, 305 306 1298 1299 O
FISH 307 311 1300 1304 O
, 311 312 1304 1305 O
or 313 315 1306 1308 O
RT 316 318 1309 1311 O
- 318 319 1311 1312 O
PCR 319 322 1312 1315 O

Primary 0 7 1316 1323 O
refractory 8 18 1324 1334 O
non 19 22 1335 1338 O
- 22 23 1338 1339 O
M3 23 25 1339 1341 O
AML 26 29 1342 1345 B-cancer

Reinstitution 0 13 1346 1359 O
of 14 16 1360 1362 O
fluconozole 17 28 1363 1374 B-treatment
, 28 29 1374 1375 O
voriconizole 30 42 1376 1388 B-treatment
, 42 43 1388 1389 O
itraconazole 44 56 1390 1402 B-treatment
, 56 57 1402 1403 O
posaconazole 58 70 1404 1416 B-treatment
, 70 71 1416 1417 O
ketokonazole 72 84 1418 1430 B-treatment
and 85 88 1431 1434 O
diltiazem 89 98 1435 1444 B-treatment
is 99 101 1445 1447 O
permissible 102 113 1448 1459 O
72 114 116 1460 1462 B-upper_bound
hours 117 122 1463 1468 I-upper_bound
after 123 128 1469 1474 O
the 129 132 1475 1478 O
last 133 137 1479 1483 O
dose 138 142 1484 1488 O
of 143 145 1489 1491 O
sirolimus 146 155 1492 1501 B-treatment

Relapsed 0 8 1502 1510 O
non 9 12 1511 1514 B-cancer
- 12 13 1514 1515 I-cancer
M3 13 15 1515 1517 I-cancer
AML 16 19 1518 1521 I-cancer

Residual 0 8 1522 1530 O
leukemia 9 17 1531 1539 B-cancer
after 18 23 1540 1545 O
a 24 25 1546 1547 O
minimum 26 33 1548 1555 O
of 34 36 1556 1558 O
2 37 38 1559 1560 B-lower_bound
prior 39 44 1561 1566 O
courses 45 52 1567 1574 O
of 53 55 1575 1577 O
chemotherapy 56 68 1578 1590 B-treatment
( 69 70 1591 1592 O
Same 70 74 1592 1596 O
or 75 77 1597 1599 O
different 78 87 1600 1609 O
) 87 88 1609 1610 O

Rifabutin 0 9 1611 1620 B-treatment
( 10 11 1621 1622 O
e.g. 11 15 1622 1626 O
, 15 16 1626 1627 O
Mycobutin 17 26 1628 1637 B-treatment
) 26 27 1637 1638 O

Rifampin 0 8 1639 1647 B-treatment
( 9 10 1648 1649 O
e.g. 10 14 1649 1653 O
, 14 15 1653 1654 O
Rifadin 16 23 1655 1662 B-treatment
) 23 24 1662 1663 O

Rifapentine 0 11 1664 1675 B-treatment
( 12 13 1676 1677 O
e.g. 13 17 1677 1681 O
, 17 18 1681 1682 O
Priftin 19 26 1683 1690 B-treatment
) 26 27 1690 1691 O

Subjects 0 8 1692 1700 O
must 9 13 1701 1705 O
be 14 16 1706 1708 O
≥ 17 18 1709 1710 O
18 19 21 1711 1713 B-lower_bound
years 22 27 1714 1719 I-lower_bound
of 28 30 1720 1722 O
age 31 34 1723 1726 B-age

Subjects 0 8 1727 1735 O
must 9 13 1736 1740 O
have 14 18 1741 1745 O
a 19 20 1746 1747 O
left 21 25 1748 1752 B-clinical_variable
ventricular 26 37 1753 1764 I-clinical_variable
ejection 38 46 1765 1773 I-clinical_variable
fraction 47 55 1774 1782 I-clinical_variable
( 56 57 1783 1784 I-clinical_variable
LVEF 57 61 1784 1788 I-clinical_variable
) 61 62 1788 1789 I-clinical_variable
of 63 65 1790 1792 O
≥ 66 67 1793 1794 O
45 68 70 1795 1797 B-lower_bound
% 70 71 1797 1798 I-lower_bound

Subjects 0 8 1799 1807 O
must 9 13 1808 1812 O
have 14 18 1813 1817 O
a 19 20 1818 1819 O
life 21 25 1820 1824 B-clinical_variable
expectancy 26 36 1825 1835 I-clinical_variable
of 37 39 1836 1838 O
at 40 42 1839 1841 O
least 43 48 1842 1847 O
4 49 50 1848 1849 B-lower_bound
weeks 51 56 1850 1855 I-lower_bound

Subjects 0 8 1856 1864 O
must 9 13 1865 1869 O
have 14 18 1870 1874 O
an 19 21 1875 1877 O
ECOG 22 26 1878 1882 B-clinical_variable
performance 27 38 1883 1894 I-clinical_variable
status 39 45 1895 1901 I-clinical_variable
of 46 48 1902 1904 O
2 49 50 1905 1906 B-upper_bound
or 51 53 1907 1909 O
less 54 58 1910 1914 O
( 59 60 1915 1916 O
see 60 63 1916 1919 O
Appendix1 64 73 1920 1929 O
) 73 74 1929 1930 O

Subjects 0 8 1931 1939 O
must 9 13 1940 1944 O
have 14 18 1945 1949 O
recovered 19 28 1950 1959 O
from 29 33 1960 1964 O
the 34 37 1965 1968 O
toxic 38 43 1969 1974 O
effects 44 51 1975 1982 O
of 52 54 1983 1985 O
any 55 58 1986 1989 O
prior 59 64 1990 1995 B-treatment
chemotherapy 65 77 1996 2008 I-treatment
to 78 80 2009 2011 O
= 81 82 2012 2013 O
< 82 83 2013 2014 O
Grade 84 89 2015 2020 B-upper_bound
1 90 91 2021 2022 I-upper_bound
( 92 93 2023 2024 O
except 93 99 2024 2030 O
alopecia 100 108 2031 2039 B-chronic_disease
) 108 109 2039 2040 O

Subjects 0 8 2041 2049 O
must 9 13 2050 2054 O
not 14 17 2055 2058 O
be 18 20 2059 2061 O
receiving 21 30 2062 2071 O
any 31 34 2072 2075 O
chemotherapy 35 47 2076 2088 B-treatment
agents 48 54 2089 2095 I-treatment
( 55 56 2096 2097 O
except 56 62 2097 2103 O
Hydroxyurea 63 74 2104 2115 B-treatment
) 74 75 2115 2116 O

Subjects 0 8 2117 2125 O
with 9 13 2126 2130 O
a 14 15 2131 2132 O
currently 16 25 2133 2142 O
active 26 32 2143 2149 B-cancer
second 33 39 2150 2156 I-cancer
malignancy 40 50 2157 2167 I-cancer

Subjects 0 8 2168 2176 O
with 9 13 2177 2181 O
uncontrolled 14 26 2182 2194 B-chronic_disease
high 27 31 2195 2199 I-chronic_disease
blood 32 37 2200 2205 I-chronic_disease
pressure 38 46 2206 2214 I-chronic_disease

Tacrolimus 0 10 2215 2225 B-treatment
( 11 12 2226 2227 O
e.g. 12 16 2227 2231 O
Prograf 17 24 2232 2239 B-treatment
) 24 25 2239 2240 O
Subjects 26 34 2241 2249 O
taking 35 41 2250 2256 O
fluconozole 42 53 2257 2268 B-treatment
, 53 54 2268 2269 O
voriconizole 55 67 2270 2282 B-treatment
, 67 68 2282 2283 O
itraconazole 69 81 2284 2296 B-treatment
, 81 82 2296 2297 O
posaconazole 83 95 2298 2310 B-treatment
, 95 96 2310 2311 O
and 97 100 2312 2315 O
ketokonazole 101 113 2316 2328 B-treatment
within 114 120 2329 2335 O
72 121 123 2336 2338 B-upper_bound
hours 124 129 2339 2344 I-upper_bound
of 130 132 2345 2347 O
study 133 138 2348 2353 O
drug 139 143 2354 2358 O
starting 144 152 2359 2367 O

Telithromycin 0 13 2368 2381 B-treatment
( 14 15 2382 2383 I-treatment
e.g. 15 19 2383 2387 I-treatment
, 19 20 2387 2388 I-treatment
Ketek 21 26 2389 2394 I-treatment
) 26 27 2394 2395 I-treatment

Verapamil 0 9 2396 2405 B-treatment
( 10 11 2406 2407 O
e.g. 11 15 2407 2411 O
, 15 16 2411 2412 O
Calan 17 22 2413 2418 B-treatment
SR 23 25 2419 2421 I-treatment
, 25 26 2421 2422 O
Isoptin 27 34 2423 2430 B-treatment
, 34 35 2430 2431 O
Verelan 36 43 2432 2439 B-treatment
) 43 44 2439 2440 O

Voriconazole 0 12 2441 2453 B-treatment
( 13 14 2454 2455 O
e.g. 14 18 2455 2459 O
, 18 19 2459 2460 O
VFEND 20 25 2461 2466 B-treatment
) 25 26 2466 2467 O

myocardial 0 10 2468 2478 B-clinical_variable
infarction 11 21 2479 2489 I-clinical_variable
within 22 28 2490 2496 O
the 29 32 2497 2500 O
past 33 37 2501 2505 B-upper_bound
6 38 39 2506 2507 I-upper_bound
months 40 46 2508 2514 I-upper_bound

negative 0 8 2515 2523 B-pregnancy
pregnancy 9 18 2524 2533 I-pregnancy
test 19 23 2534 2538 O
for 24 27 2539 2542 O
women 28 33 2543 2548 B-gender
with 34 38 2549 2553 O
child 39 44 2554 2559 O
- 44 45 2559 2560 O
bearing 45 52 2560 2567 O
potential 53 62 2568 2577 O

non 0 3 2578 2581 B-cancer
- 3 4 2581 2582 I-cancer
melanoma 4 12 2582 2590 I-cancer
skin 13 17 2591 2595 I-cancer
cancers 18 25 2596 2603 I-cancer

serious 0 7 2604 2611 O
uncontrolled 8 20 2612 2624 O
cardiac 21 28 2625 2632 B-chronic_disease
arrhythmia 29 39 2633 2643 I-chronic_disease

symptomatic 0 11 2644 2655 O
congestive 12 22 2656 2666 B-chronic_disease
heart 23 28 2667 2672 I-chronic_disease
failure 29 36 2673 2680 I-chronic_disease

total 0 5 2681 2686 B-clinical_variable
or 6 8 2687 2689 I-clinical_variable
direct 9 15 2690 2696 I-clinical_variable
bilirubin 16 25 2697 2706 I-clinical_variable
≤ 26 27 2707 2708 O
1.5mg 28 33 2709 2714 B-upper_bound
/ 33 34 2714 2715 I-upper_bound
dL 34 36 2715 2717 I-upper_bound
; 36 37 2717 2718 O
SGPT 38 42 2719 2723 B-clinical_variable
( 43 44 2724 2725 I-clinical_variable
ALT 44 47 2725 2728 I-clinical_variable
) 47 48 2728 2729 I-clinical_variable
≤ 49 50 2730 2731 O
3xULN 51 56 2732 2737 B-upper_bound

unstable 0 8 2738 2746 B-chronic_disease
angina 9 15 2747 2753 I-chronic_disease

